Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C81H113N21O25S3 |
| Molecular Weight | 1877.085 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 12 / 12 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC(=O)OCN([C@H](C[C@@H](OC(C)=O)C1=NC(=CS1)C(=O)N[C@H](C[C@H](C)C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)CC[C@H](NC(=O)C2=CC=C(NCC3=NC4=C(N=C3)N=C(N)NC4=O)C=C2)C(O)=O)C(O)=O)CC5=CC=C(O)C=C5)C(C)C)C(=O)[C@@H](NC(=O)[C@H]6CCCCN6C)[C@@H](C)CC
InChI
InChIKey=CDSJGIIWNPXYAR-QURSGCAYSA-N
InChI=1S/C81H113N21O25S3/c1-9-14-63(110)126-40-102(76(119)64(42(5)10-2)96-73(117)57-16-11-12-28-101(57)8)58(41(3)4)35-59(127-44(7)103)75-95-55(38-128-75)72(116)89-48(32-45-17-23-50(104)24-18-45)31-43(6)67(111)99-100-81(124)125-29-30-129-130-39-56(78(122)123)94-71(115)54(34-62(108)109)93-69(113)51(15-13-27-85-79(82)83)91-70(114)53(33-61(106)107)90-60(105)26-25-52(77(120)121)92-68(112)46-19-21-47(22-20-46)86-36-49-37-87-66-65(88-49)74(118)98-80(84)97-66/h17-24,37-38,41-43,48,51-54,56-59,64,86,104H,9-16,25-36,39-40H2,1-8H3,(H,89,116)(H,90,105)(H,91,114)(H,92,112)(H,93,113)(H,94,115)(H,96,117)(H,99,111)(H,100,124)(H,106,107)(H,108,109)(H,120,121)(H,122,123)(H4,82,83,85)(H3,84,87,97,98,118)/t42-,43-,48+,51-,52-,53-,54-,56-,57+,58+,59+,64-/m0/s1
| Molecular Formula | C81H113N21O25S3 |
| Molecular Weight | 1877.085 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 12 / 12 |
| E/Z Centers | 4 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:47:12 GMT 2025
by
admin
on
Tue Apr 01 16:47:12 GMT 2025
|
| Record UNII |
XBG8SF1OJB
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
EC-0305
Created by
admin on Tue Apr 01 16:47:12 GMT 2025 , Edited by admin on Tue Apr 01 16:47:12 GMT 2025
|
PRIMARY | F0305 - Anti-FANCD2 antibody produced in rabbit | ||
|
24773035
Created by
admin on Tue Apr 01 16:47:12 GMT 2025 , Edited by admin on Tue Apr 01 16:47:12 GMT 2025
|
PRIMARY | |||
|
1059477-97-2
Created by
admin on Tue Apr 01 16:47:12 GMT 2025 , Edited by admin on Tue Apr 01 16:47:12 GMT 2025
|
PRIMARY | |||
|
XBG8SF1OJB
Created by
admin on Tue Apr 01 16:47:12 GMT 2025 , Edited by admin on Tue Apr 01 16:47:12 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
When tested against more chemoresistant folate receptor expressing M109 and 4T1-cl2 tumors, EC0305 displayed superior antitumor activity over a previously disclosed folate conjugate of desacetylvinblastine monohydrazide (EC145). These studies demonstrate that EC0305 has significant antiproliferative activity against FR expressing tumors, including those which are generally more chemoresistant, and that EC0305 should be considered
for development as a candidate for the treatment of advanced FR-expressing human cancers.
|